NYSE - NYSE Delayed Price. Currency in USD
298.980.00 (0.00%)
As of 4:03 PM EDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close298.98
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
Avg Vol (3m)N/A
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Allergan Gets FDA Approval for New Line of Breast Implants
    Zacks3 hours ago

    Allergan Gets FDA Approval for New Line of Breast Implants

    Allergan plc (AGN) announced that the FDA has approved the Natrelle Inspira Cohesive line of breast implants for breast reconstruction, augmentation or revision surgery.

  • TheStreet.com4 days ago

    Gilead Sciences (GILD) Stock Lower Despite Bullish Gabelli Note

    Gilead Sciences' (GILD) NASH liver disease pipeline is "very attractive," Gabelli said in an analyst note on Thursday.

  • Barrons.com4 days ago

    [$$] Teva, Allergan Pump Up the Pipelines

    Credit Suisse Teva Pharmaceutical Industries and Allergan both took eye-opening steps in announcing deals to bring in new pipeline assets that may help drive mid- to longer-term growth. Of the two, Teva’s (TEVA) new partnership with Regeneron Pharmaceuticals (REGN) on fasinumab seems a little more reasonable to us when considering the price paid and the clearer overlap with Teva’s existing infrastructure, while Allergan’s (AGN) decision to pay a very large premium (especially when the contingent value rights (CVRs) are factored in) to move into the non-alcoholic steatohepatitis (NASH) space through the acquisition of Tobira Therapeutics (TBRA) was more of a surprise to us. Teva has highlighted pain as one of their core areas of focus so a collaboration to obtain access to Regeneron’s fasinumab ties in to strategy.